These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 11130522)

  • 1. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials.
    Pahor M; Psaty BM; Alderman MH; Applegate WB; Williamson JD; Cavazzini C; Furberg CD
    Lancet; 2000 Dec; 356(9246):1949-54. PubMed ID: 11130522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
    Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
    JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-blockers for hypertension.
    Wiysonge CS; Bradley H; Mayosi BM; Maroney R; Mbewu A; Opie LH; Volmink J
    Cochrane Database Syst Rev; 2007 Jan; (1):CD002003. PubMed ID: 17253471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis.
    Psaty BM; Smith NL; Siscovick DS; Koepsell TD; Weiss NS; Heckbert SR; Lemaitre RN; Wagner EH; Furberg CD
    JAMA; 1997 Mar; 277(9):739-45. PubMed ID: 9042847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.
    Neal B; MacMahon S; Chapman N;
    Lancet; 2000 Dec; 356(9246):1955-64. PubMed ID: 11130523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular protection and blood pressure reduction: a meta-analysis.
    Staessen JA; Wang JG; Thijs L
    Lancet; 2001 Oct; 358(9290):1305-15. PubMed ID: 11684211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
    Chaugai S; Sherpa LY; Sepehry AA; Kerman SRJ; Arima H
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):433-445. PubMed ID: 29739234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2015 Feb; 33(2):195-211. PubMed ID: 25485720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should calcium antagonists be first line drugs in hypertension?
    Furberg CD; Psaty BM
    Herz; 1995 Dec; 20(6):365-9. PubMed ID: 8582696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
    Costanzo P; Perrone-Filardi P; Petretta M; Marciano C; Vassallo E; Gargiulo P; Paolillo S; Petretta A; Chiariello M
    J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of hypertension in the elderly].
    Hohage H; Gerhardt U; Suwelack BM
    Med Klin (Munich); 2003 Sep; 98(9):511-21. PubMed ID: 14551708
    [No Abstract]   [Full Text] [Related]  

  • 15. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
    Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
    Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of first-line antihypertensives.
    Strickland C
    J Fam Pract; 1997 Jun; 44(6):530-1. PubMed ID: 9191619
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial].
    Scheen AJ; Krzesinski JM
    Rev Med Liege; 2003 Jan; 58(1):47-52. PubMed ID: 12647599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease.
    Bangalore S; Fayyad R; Laskey R; Demicco DA; Deedwania P; Kostis JB; Messerli FH;
    Am J Med; 2014 Jan; 127(1):71-81.e1. PubMed ID: 24210549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure--meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2016 Mar; 34(3):373-84; discussion 384. PubMed ID: 26780184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.